CAPS Medical, an Or Yehuda, Israel-based developer focused on cold atmospheric plasma (CAP) to treat cancer, reported the completion of a $3.5 million series A financing round. The round will enable the company to perform its first clinical trial and assist the company in further developing its portfolio for treatments of solid tumors. It expects that the results of these studies will contribute to achieving regulatory clearance in the U.S. market. Harel Gadot, company group chairman of Medx Ventures Group and executive chairman of Xact Robotics, will serve as the executive chairman of CAPS Medical's board.
Paris-based DNA Script reported a $50 million extension to its series B financing, bringing the total investment of this round to $89 million. This oversubscribed round is led by Casdin Capital and joined by Danaher Life Sciences, Agilent Technologies, Merck KGaA through its corporate venture arm, M Ventures, as well as three of the world’s leaders in oligo synthesis: LSP, the Bpifrance Large Venture Fund and Illumina Ventures. Eli Casdin, founder and chief investment officer of Casdin Capital, will join DNA Script’s board. Funding from this round will enable DNA Script to accelerate the development of its suite of enzymatic DNA synthesis technologies – in particular, to support the commercial launch of the company’s Syntax DNA benchtop printer.
Eargo, a San Jose, Calif.-based medical device company that is aiming to improve the quality of life of people with hearing loss, reported the closing of a $71 million equity financing, led by new co-investors Gilde Healthcare and Longitude Capital, with existing investors New Enterprise Associates, the Charles and Helen Schwab Foundation and Nan Fung Life Sciences also participating. Geoff Pardo of Gilde Healthcare and Juliet Tammenoms Bakker of Longitude Capital will join Eargo's board. The financing provides Eargo with additional capital to expand commercialization during a period of accelerated consumer demand for its direct-to-consumer hearing loss solution.
Cambridge, Mass.-based Omega Therapeutics Inc., which is focused on a new category of genomic medicine through epigenomic programming, reported the completion of an $85 million financing. The funding will support progression to first-in-human clinical trials of the company’s Epigenomic Controllers for programs in oncology, inflammation, autoimmune, metabolic and rare genetic diseases.
Stamford, Conn.-based Sema4, a patient-centered health intelligence company, said that funds managed by Blackrock led its oversubscribed series C financing of $121 million at a post-money valuation of more than $1 billion. Additional new investors include Deerfield Management Co. and Moore Strategic Ventures. Each of the investors from Sema4’s first round of external funding participated in this second round, including Blackstone, Section 32, Oak HC/FT, Decheng, and Connecticut Innovations. In addition, Andrew Elbardissi, partner at Deerfield, has joined Sema4’s board. Sema4 also recently added Mike Pellini, from Section32 (former CEO of Foundation Medicine), Rachel Sherman (former principal deputy commissioner at the FDA) and Marty Chavez (former CFO of Goldman Sachs) to its board.